Patents by Inventor Mark VANDERWAL
Mark VANDERWAL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250276976Abstract: Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2A, R2B, R3, R4, and R5 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: January 8, 2025Publication date: September 4, 2025Inventors: Chihyuan CHUANG, Bradley P. Morgan, Mark Vanderwal, Luke W. Ashcraft, Kevin Lau
-
Patent number: 12275741Abstract: Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2A, R2B, R3, R4, and R5 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.Type: GrantFiled: February 26, 2024Date of Patent: April 15, 2025Assignee: Cytokinetics, Inc.Inventors: Chihyuan Chuang, Bradley P. Morgan, Mark Vanderwal, Luke W. Ashcraft, Kevin Lau
-
Publication number: 20250059173Abstract: Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein A, Z, B, R1, R2, R3, G1, G2, and G3 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: July 2, 2024Publication date: February 20, 2025Inventors: Chihyuan CHUANG, Bradley P. MORGAN, Mark VANDERWAL, Wenyue WANG, Luke W. ASHCRAFT
-
Patent number: 12187712Abstract: Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2, Y1, Y2, L1, and G1 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.Type: GrantFiled: June 25, 2019Date of Patent: January 7, 2025Assignee: CYTOKINETICS, INC.Inventors: Bradley P. Morgan, Mark Vanderwal, Chihyuan Chuang
-
Publication number: 20240368172Abstract: Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2A, R2B, R3, R4, and R5 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: February 26, 2024Publication date: November 7, 2024Inventors: Chihyuan CHUANG, Bradley P. MORGAN, Mark VANDERWAL, Luke W. ASHCRAFT, Kevin LAU
-
Patent number: 11952381Abstract: Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2A, R2B, R3, R4, and R5 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 4, 2022Date of Patent: April 9, 2024Assignee: CYTOKINETICS, INC.Inventors: Chihyuan Chuang, Bradley P. Morgan, Mark Vanderwal, Luke W. Ashcraft, Kevin Lau
-
Publication number: 20230119665Abstract: Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein A, Z, B, R1, R2, R3, G1, G2, and G3 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: August 31, 2022Publication date: April 20, 2023Inventors: Chihyuan CHUANG, Bradley P. MORGAN, Mark VANDERWAL, Wenyue WANG, Luke W. ASHCRAFT
-
Publication number: 20230090256Abstract: Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2A, R2B, R3, R4, and R5 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: May 4, 2022Publication date: March 23, 2023Inventors: Chihyuan CHUANG, Bradley P. MORGAN, Mark VANDERWAL, Luke W. ASHCRAFT, Kevin LAU
-
Patent number: 11472796Abstract: Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein A, Z, B, R1, R2, R3, G1, G2, and G3 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.Type: GrantFiled: September 4, 2020Date of Patent: October 18, 2022Assignee: CYTOKINETICS, INC.Inventors: Chihyuan Chuang, Bradley P. Morgan, Mark Vanderwal, Wenyue Wang, Luke W. Ashcraft
-
Patent number: 11414424Abstract: Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2A, R2B, R3, R4, and R5 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.Type: GrantFiled: August 30, 2019Date of Patent: August 16, 2022Assignee: CYTOKINETICS, INC.Inventors: Chihyuan Chuang, Bradley P. Morgan, Mark Vanderwal, Luke W. Ashcraft, Kevin Lau
-
Publication number: 20210276991Abstract: Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2, Y1, Y2, L1, and G1 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: June 25, 2019Publication date: September 9, 2021Inventors: Bradley P. MORGAN, Mark VANDERWAL, Chihyuan CHUANG
-
Publication number: 20210147399Abstract: Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein A, Z, B, R1, R2, R3, G1, G2, and G3 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: September 4, 2020Publication date: May 20, 2021Inventors: Chihyuan CHUANG, Bradley P. MORGAN, Mark VANDERWAL, Wenyue WANG, Luke W. ASHCRAFT
-
Patent number: 10836755Abstract: Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein A, Z, B, R1, R2, R3, G1, G2, and G3 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.Type: GrantFiled: January 18, 2019Date of Patent: November 17, 2020Assignee: CYTOKINETICS, INC.Inventors: Chihyuan Chuang, Bradley P. Morgan, Mark Vanderwal, Wenyue Wang, Luke W. Ashcraft
-
Publication number: 20200109148Abstract: Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2A, R2B, R3, R4, and R5 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: August 30, 2019Publication date: April 9, 2020Inventors: Chihyuan CHUANG, Bradley P. MORGAN, Mark VANDERWAL, Luke W. ASHCRAFT, Kevin LAU
-
Publication number: 20190256504Abstract: Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein A, Z, B, R1, R2, R3, G1, G2, and G3 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: January 18, 2019Publication date: August 22, 2019Inventors: Chihyuan CHUANG, Bradley P. MORGAN, Mark VANDERWAL, Wenyue WANG, Luke W. ASHCRAFT
